These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 17540336)
1. Structural insight into the altered substrate specificity of human cytochrome P450 2A6 mutants. Sansen S; Hsu MH; Stout CD; Johnson EF Arch Biochem Biophys; 2007 Aug; 464(2):197-206. PubMed ID: 17540336 [TBL] [Abstract][Full Text] [Related]
2. Expansion of substrate specificity of cytochrome P450 2A6 by random and site-directed mutagenesis. Wu ZL; Podust LM; Guengerich FP J Biol Chem; 2005 Dec; 280(49):41090-100. PubMed ID: 16215230 [TBL] [Abstract][Full Text] [Related]
3. Identification of Val117 and Arg372 as critical amino acid residues for the activity difference between human CYP2A6 and CYP2A13 in coumarin 7-hydroxylation. He XY; Shen J; Hu WY; Ding X; Lu AY; Hong JY Arch Biochem Biophys; 2004 Jul; 427(2):143-53. PubMed ID: 15196988 [TBL] [Abstract][Full Text] [Related]
4. Analysis of coumarin 7-hydroxylation activity of cytochrome P450 2A6 using random mutagenesis. Kim D; Wu ZL; Guengerich FP J Biol Chem; 2005 Dec; 280(48):40319-27. PubMed ID: 16207711 [TBL] [Abstract][Full Text] [Related]
5. Random mutagenesis of human cytochrome p450 2A6 and screening with indole oxidation products. Nakamura K; Martin MV; Guengerich FP Arch Biochem Biophys; 2001 Nov; 395(1):25-31. PubMed ID: 11673862 [TBL] [Abstract][Full Text] [Related]
6. Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Melet A; Marques-Soares C; Schoch GA; Macherey AC; Jaouen M; Dansette PM; Sari MA; Johnson EF; Mansuy D Biochemistry; 2004 Dec; 43(49):15379-92. PubMed ID: 15581350 [TBL] [Abstract][Full Text] [Related]
7. Kinetic analysis of oxidation of coumarins by human cytochrome P450 2A6. Yun CH; Kim KH; Calcutt MW; Guengerich FP J Biol Chem; 2005 Apr; 280(13):12279-91. PubMed ID: 15665333 [TBL] [Abstract][Full Text] [Related]
8. Biosynthesis of new indigoid inhibitors of protein kinases using recombinant cytochrome P450 2A6. Wu ZL; Aryal P; Lozach O; Meijer L; Guengerich FP Chem Biodivers; 2005 Jan; 2(1):51-65. PubMed ID: 17191919 [TBL] [Abstract][Full Text] [Related]
9. Key residues controlling binding of diverse ligands to human cytochrome P450 2A enzymes. DeVore NM; Smith BD; Wang JL; Lushington GH; Scott EE Drug Metab Dispos; 2009 Jun; 37(6):1319-27. PubMed ID: 19251817 [TBL] [Abstract][Full Text] [Related]
10. Identification of amino acid residues involved in 4-chloroindole 3-hydroxylation by cytochrome P450 2A6 using screening of random libraries. Zhang ZG; Liu Y; Guengerich FP; Matse JH; Chen J; Wu ZL J Biotechnol; 2009 Jan; 139(1):12-8. PubMed ID: 18984015 [TBL] [Abstract][Full Text] [Related]
11. Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. Yano JK; Denton TT; Cerny MA; Zhang X; Johnson EF; Cashman JR J Med Chem; 2006 Nov; 49(24):6987-7001. PubMed ID: 17125252 [TBL] [Abstract][Full Text] [Related]
12. Homology modelling of CYP2A6 based on the CYP2C5 crystallographic template: enzyme-substrate interactions and QSARs for binding affinity and inhibition. Lewis DF; Lake BG; Dickins M; Goldfarb PS Toxicol In Vitro; 2003 Apr; 17(2):179-90. PubMed ID: 12650672 [TBL] [Abstract][Full Text] [Related]
13. Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. Yano JK; Hsu MH; Griffin KJ; Stout CD; Johnson EF Nat Struct Mol Biol; 2005 Sep; 12(9):822-3. PubMed ID: 16086027 [TBL] [Abstract][Full Text] [Related]
14. Structural diversity of human xenobiotic-metabolizing cytochrome P450 monooxygenases. Johnson EF; Stout CD Biochem Biophys Res Commun; 2005 Dec; 338(1):331-6. PubMed ID: 16157296 [TBL] [Abstract][Full Text] [Related]
15. Development of models for cytochrome P450 2A5 as well as two of its mutants. Stahl GR; Höltje HD Pharmazie; 2005 Apr; 60(4):247-53. PubMed ID: 15881601 [TBL] [Abstract][Full Text] [Related]
16. Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. Lewis DF Arch Biochem Biophys; 2003 Jan; 409(1):32-44. PubMed ID: 12464242 [TBL] [Abstract][Full Text] [Related]
17. Coumarin Derivatives as Substrate Probes of Mammalian Cytochromes P450 2B4 and 2B6: Assessing the Importance of 7-Alkoxy Chain Length, Halogen Substitution, and Non-Active Site Mutations. Liu J; Shah MB; Zhang Q; Stout CD; Halpert JR; Wilderman PR Biochemistry; 2016 Apr; 55(13):1997-2007. PubMed ID: 26982502 [TBL] [Abstract][Full Text] [Related]
18. Identification of critical amino acid residues of human CYP2A13 for the metabolic activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific carcinogen. He XY; Shen J; Ding X; Lu AY; Hong JY Drug Metab Dispos; 2004 Dec; 32(12):1516-21. PubMed ID: 15333516 [TBL] [Abstract][Full Text] [Related]
19. Inhibitory potency of 8-methoxypsoralen on cytochrome P450 2A6 (CYP2A6) allelic variants CYP2A6 15, CYP2A6 16, CYP2A6 21 and CYP2A6 22: differential susceptibility due to different sequence locations of the mutations. Tiong KH; Mohammed Yunus NA; Yiap BC; Tan EL; Ismail R; Ong CE PLoS One; 2014; 9(1):e86230. PubMed ID: 24475091 [TBL] [Abstract][Full Text] [Related]
20. Analysis of differential substrate selectivities of CYP2B6 and CYP2E1 by site-directed mutagenesis and molecular modeling. Spatzenegger M; Liu H; Wang Q; Debarber A; Koop DR; Halpert JR J Pharmacol Exp Ther; 2003 Jan; 304(1):477-87. PubMed ID: 12490624 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]